Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...